This review is a summary of a recent event in Sydney on changing the treatment paradigm in iNHL and MCL. The presenter was Professor Martin Dreyling, Professor of Medicine and Head of the Lymphoma Programme in the Department of Medicine III, University Hospital Groβhadern, Ludwig Maximilians-University in Munich.
This publication covers:
- Indolent NHL subtypes
- Optimal induction regimens
- Anti-CD20 monoclonal antibody therapy
- MCL: chemotherapy standards in first-line
- MCL: a general summary
Please login below to download this issue (PDF)